Diadema Partners LP Verve Therapeutics, Inc. Transaction History
Diadema Partners LP
- $383 Billion
- Q1 2025
A detailed history of Diadema Partners LP transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 116,900 shares of VERV stock, worth $509,684. This represents 0.14% of its overall portfolio holdings.
Number of Shares
116,900Holding current value
$509,684% of portfolio
0.14%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding VERV
# of Institutions
203Shares Held
79.5MCall Options Held
204KPut Options Held
101K-
Alphabet Inc. Mountain View, CA12.3MShares$53.8 Million5.03% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$30.1 Million1.39% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$28.9 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$17.4 Million2.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$17.2 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $261M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...